Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2018-09-21 (7 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: VIC-EN-BIGORRE (65500), Hautes-Pyrenees
PHARMACIE LACAZE : revenue, balance sheet and financial ratios
PHARMACIE LACAZE is a French company
founded 7 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in VIC-EN-BIGORRE (65500),
this company of category PME
shows in 2023 a revenue of 2.8 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE LACAZE (SIREN 842522773)
Indicator
2024
2023
2022
2021
2020
2019
Revenue
N/C
2 780 354 €
2 550 382 €
2 400 276 €
2 349 975 €
N/C
Net income
185 971 €
116 836 €
135 665 €
229 817 €
178 401 €
106 239 €
EBITDA
N/C
136 867 €
148 737 €
180 312 €
219 395 €
N/C
Net margin
N/C
4.2%
5.3%
9.6%
7.6%
N/C
Revenue and income statement
In 2024, PHARMACIE LACAZE generates positive net income of 186 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2019-2024: 106 k€ -> 186 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
185 971 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 97%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 43%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
96.836%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
43.108%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2022
2023
2024
Debt ratio
835.631
414.32
236.625
173.627
134.052
96.836
Financial autonomy
9.374
17.341
26.593
32.033
36.33
43.108
Repayment capacity
None
7.5
6.068
8.888
8.909
None
Cash flow / Revenue
None%
9.008%
9.941%
5.742%
4.69%
None%
Sector positioning
Debt ratio
96.842024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Average-13 pts over 3 years
In 2024, the debt ratio of PHARMACIE LACAZE (96.84) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
43.11%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average+12 pts over 3 years
In 2024, the financial autonomy of PHARMACIE LACAZE (43.1%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
8.91 years2023
2022
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of PHARMACIE LACAZE (8.91) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 181.61. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
181.607
Liquidity indicators evolution PHARMACIE LACAZE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2019
2020
2021
2022
2023
2024
Liquidity ratio
137.249
177.506
196.775
176.598
162.959
181.607
Interest coverage
None
3.24
3.298
2.95
2.793
None
Sector positioning
Liquidity ratio
181.612024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Average+10 pts over 3 years
In 2024, the liquidity ratio of PHARMACIE LACAZE (181.61) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
2.79x2023
2022
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Good
In 2023, the interest coverage of PHARMACIE LACAZE (2.8x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE LACAZE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
222 096 €
215 905 €
247 642 €
266 163 €
0 €
Inventory turnover (days)
0
35
37
35
37
0
Customer payment term (days)
0
6
4
5
5
0
Supplier payment term (days)
0
35
33
40
47
0
Positioning of PHARMACIE LACAZE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE LACAZE is estimated at
2 596 292 €
(range 1 808 017€ - 3 884 202€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1808k€2596k€3884k€
2 596 292 €Range: 1 808 017€ - 3 884 202€
NAF 5 année 2024
Valuation method used
Net Income Multiple
185 971 €
×
14.0x
=2 596 293 €
Range: 1 808 017€ - 3 884 202€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE LACAZE with other companies in the same sector:
The revenue of PHARMACIE LACAZE in 2023 is 2.8 M€.
Is PHARMACIE LACAZE profitable?
Yes, PHARMACIE LACAZE generated a net profit of 186 k€ in 2024.
Where is the headquarters of PHARMACIE LACAZE ?
The headquarters of PHARMACIE LACAZE is located in VIC-EN-BIGORRE (65500), in the department Hautes-Pyrenees.
Where to find the tax return of PHARMACIE LACAZE ?
The tax return of PHARMACIE LACAZE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE LACAZE operate?
PHARMACIE LACAZE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart